# A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

> **NCT06765317** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 42 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma (DLBCL)
- High Grade B Cell Lymphoma

## Interventions

- **DRUG:** Glofitamab
- **DRUG:** Polatuzumab
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Obinutuzumab:

## Key facts

- **NCT ID:** NCT06765317
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-16
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06765317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06765317, "A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06765317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*